Montelukast or equivalent

DRUG2 trials

Sponsors

Sanofi

Conditions

Immune System DisorderPlasma Cell Myeloma

Phase 1

Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation

TerminatedNCT04294459

SanofiImmune System Disorder

Start: 2020-06-18End: 2022-05-02Updated: 2025-09-17

Phase 3

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Active, not recruitingNCT04270409

SanofiPlasma Cell Myeloma

Start: 2020-06-16End: 2033-10-21Updated: 2025-12-12

Related Papers

Final results of a multi-center phase 2 trial of isatuximab-lenalidomide in patients with high risk smoldering multiple myeloma (HRSMM)

Blood2025-11-03

Anti-HLA serologic response to CD38-targeting desensitization therapy is challenged by peripheral memory B cells in highly sensitized kidney transplant candidates.

2024-08-1013 citations

Isatuximab Monotherapy for Desensitization in Highly Sensitized Patients Awaiting Kidney Transplant

Journal of the American Society of Nephrology2023-12-2629 citations

ISAMAR: Multicenter phase II single arm trial of isatuximab (ISA) with/without lenalidomide (LEN) in pts with high risk smoldering multiple myeloma (HRSMM).

Journal of Clinical Oncology2023-06-013 citations

Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study

Blood2022-11-158 citations